报告题目:Nanomedicine in cancer immunotherapy         

报 告 人:Dr. Weijing Yang

 Laboratory of Molecular Imaging and Nanomedicine

 National Institute of Biomedical Imaging and Bioengineering

 National Institutes of Health

报告时间:2019年12月27日（星期五）上午8:30-9:30

报告地点:独墅湖校区912号楼730室

报告摘要:Cancer immunotherapy has emerged as one of the most important treatment modalities for cancer in the past two decades. Owing to tumor heterogeneity, monotherapy is generally diffcult to yield satisfactory treatment outcomes. Combination therapy based on multiple therapeutic pathways has become a mainstay in cancer immunotherapy. Herein, we mainly mention the combinational therapy based on photodynamic therapy （PDT），chemotherapy and tumor microenvironment modulation. In the first part, we constructed a versatile polymersomal nanoformulation that enables generation of tumor-associated antigens (TAAs) and imultaneously serves as adjuvant for an in situ DC vaccine is reported. In the second part, we serendipitously found that the pH-responsive nanovesicles (pRNVs) self-assembled from block copolymer polyethylene glycol-b-cationic polypeptide (PEG-b-cPPT) can not only serve as a nanocarrier but also cause immunogenic cell death (ICD) through pre-apoptotic exposure of calreticulin (CRT).

报告人简介：Dr. Weijing Yang graduated from Soochow University (2017) for her Ph.D in exploiting polyemrsomal nanomedicine for cancer therapy, when she joined the National Institutes of Health for postdoctoral study in cancer immunotherapy. She mainly concentrated on photodynamic therapy/chemotherapy/tumor microenvironment modulation for combinational cancer immunotherapy, as well as using specific function of nanocarrier (e.g., adjuvant or immunogenic cell death). Nowadays, she has published a series of papers in some top journals including Adv. Mater., Nano Today, ACS Nano, Chem. Mater., J. Control. Release etc.

（报告联系人：孙欢利）